Medesis Pharma S.A. (EPA:ALMDP)

Market Cap	1.77M
Revenue (ttm)	63.64K
Net Income (ttm)	-3.13M
Shares Out	5.06M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	0.3500
Day's Range	n/a
52-Week Range	0.3000 - 2.0000
Beta	0.18
RSI	40.91
Earnings Date	Apr 17, 2025

About Medesis Pharma

Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMDP

Financial Performance

In 2023, Medesis Pharma's revenue was 300,034, an increase of 52.07% compared to the previous year's 197,297. Losses were -3.96 million, 44.0% more than in 2022.